Shares of Jasper Therapeutics, Inc. (JSPR) are continuing their rally from Wednesday when the clinical-stage biotechnology company's stock rose on the news that Oppenheimer initiated coverage on the company with outperform rating. The stock are gaining over 30% on Friday morning.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
JSPR is currently trading at $16.37, up $3.89 or 31.14%, on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.